C-HQSVGEn1E Lifesciences
dual signal modulators, kinase modulation, AI drug discovery
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-HQSV
C-HQSVC-HQSVdual signal modulators, kinase modulation, AI drug discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
In this episode of Our Own Devices, our host Nandagopal Rajan, CEO, The Indian Express Digital is joined by serial entrepreneur Soujanya Bhumkar, and Ritu Lal, CEO and Co-founder, GEn1E Lifesciences Inc. Today's conversation centres around using AI for discovering and developing drugs at a fast pace. As far as the field of biotechnology is concerned, a major use case for artificial intelligence is discovering and developing personalised drugs that can help solve more specific conditions and diseases, or specified strains of different illnesses. To learn more about how this is being done, tune into Our Own Devices with Nandagopal Rajan. 00:00 Introduction 2:33 What does Genie do? 7:20 How is AI helping Genie 10:35 How is experience helping in drug development and how do collaborations on data work 16:53 How things are changing and what challenges are being faced 21:37 Is drug delivery going to get increasingly personalised? 24:21 How does India fit into this? The Indian Express cove
The goal of this clinical trial is to determine the pharmacokinetics (how the body interacts with administered substances for the entire duration of exposure) of Gen-1124 in an oral formulation (taken by mouth) in healthy volunteers. It will also learn about the safety of Gen-1124. The main questions it aims to answer are: \- How does Gen-1124 interact with a human body? Researchers will look at how Gen-1124 interacts with the body and what side effects it may cause. Participants will: * Take Gen-1124 for a single dose * Remain in clinic for 2 days for checkups and tests * Recieve a phone call for a checkup 3 and 7 days after the single dose
GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis. Subjects will be given a second dose approximately 8 hours after the first dose and will continue with twice daily dosing (BID regimen) for 5 days.
In this early phase clinical research study, the investigational drug will be administered to 64 healthy volunteers in a double-blind, placebo-controlled manner, at a one research center. The objectives of the study are to assess what the body does to the investigational drug, what the investigational drug does to the body and also to observe the safety and tolerability of the investigational drug healthy volunteers.
►►► Subscribe free: http://bit.ly/YavisBreakingNews New York In the midst of every crisis lies opportunity. Silicon Valley entrepreneurs are creating startups or pivoting existing ones to fight Covid-19. Some companies have raised funding with the help of Y Combinator, or were formed after discussions in the Covid Accelerator, a community that helps startups develop and raise funding. "The current situation is creating an unprecedented change to consumer behavior," Jared Friedman, a partner at Y Combinator, told CNN Business. "There are huge opportunities for new products to help people with our new daily reality." This isn't the first time that a downturn has led to game-changing innovations. Two of Y-Combinator's most successful companies, online payment platform Stripe and Airbnb, were created in the midst of the 2008 financial crisis. As people a decade ago sought ways to make money in the depths of a recession, they listed parts of their home out on Airbnb. Uber, founded in
Gen1e Lifesciences receives US FDA designations for GEn-1123 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA
Gen1e Lifesciences presents new ERK inhibitors | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes a
GEn1E and Rubicon Research Announce Strategic Partnership to Advance AI-Driven Precision Immunomodulators - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases GEn1E and Rubicon Research Announce Strategic Partnership to Advance AI-Driven Precision Immunomodulators April 21, 2026 | 3 min read Twitter LinkedIn Facebook Email Print PALO ALTO, Calif.--(BUSINESS WIRE)--GEn1E Lifesciences Inc., a Phase 2 clinical-stage biotechnology company advancing AI-driven novel … nce the scalability and capital efficiency of GEn1E’s platform by extending its application across additional therapeutic areas, while strengthening the company’s ability to translate its pipeline into differentiated, commercially viable products. By combining GEn1E’s precision medicine engine with Rubicon’s formulations development and commercialization infrastructure, the collaboration aims to expand access to targeted therapies for patients with high unmet medical need. “P … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
GEn1E Lifesciences DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News --> PHARMA COMPASS Grow Your Pharma Business Digitally --> --> --> Meet Us --> All API FDF Price Company Services Excipients Market Place Sourcing Support Login Find Suppliers : (API/FDF) --> Find Suppliers : API/FDF Search Our Integrated Database Services Questionnaire For Your Search - Analytical - Analytical Method Development - Biologic Drugs - Capillary Electrophoresis - Chiral HPLC & SFC Method Development - Impurity Isolation a … The email can't be empty Please enter a valid email. The mobile can't be empty Submit Privacy policy Terms and conditions Disclaimers Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale. --> Product listings are provided for informational purposes only. We do not supply
Gen1e Lifesciences discloses MAPK14 inhibitors | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes a
Media | GEn1E Lifesciences Pipeline Phase 2 Study Differentiation AI Platform Partners About Media Contact Us Contact us Stay Updated News, Publications & Events Stay updated on groundbreaking achievements, explore noteworthy publications, and mark your calendar for upcoming events that shape our collective story. Listen to the GEn1E Podcast about NextGen Dual Signal Modulators! More about GEn1E News Publications Events News GEn1E and Rubicon Research Announce Strategic Partnership to Advance AI-Driven Precision Immunomodulators News How Geopolitics Is Shaping AI Drug Development: A Silico
GEn1E Lifesciences Announces Partnership with BARDA to Advance its AI-powered Endotyping Program for ARDS Patients to Further Accelerate its Novel, Lead Compound GEn-1124 Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company En … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
GEn1E Lifesciences: AI platform accelerating therapies for rare & inflammatory diseases. | Y Combinator Open menu About What Happens at YC? Apply YC Interview Guide FAQ People YC Blog Companies Startup Directory Founder Directory Launch YC Library Partners Resources Startup School Newsletter Requests for Startups For Investors Verify Founders Hacker News Bookface Safe Find a Co-Founder Startup Jobs Log in Apply Home › Companies › GEn1E Lifesciences GEn1E Lifesciences AI platform accelerating therapies for rare & inflammatory diseases. Y Combinator Logo Summer 2019 Active Artificial Int
GEn1E Lifesciences Pipeline Phase 2 Study Differentiation AI Platform Partners About Media Contact Us Contact us GEn1E welcomes François Nader, MD, as our Chairman of the Board Read more Dr. Mizushima-San joins GEn1E as a strategic advisor for Japan! Read announcement FORBES JAPAN: How Geopolitics Is Shaping AI Drug Development: A Silicon Valley Company’s View Read Forbes Japan Article We are a clinical-stage, Phase 2 Company Accelerating 1 st -in-class precision therapies for inflammatory & rare diseases We accelerated from Early Discovery to Phase 2 in 2.5 years with seed capital PIPELIN
GEn1E Lifesciences - Advisory Team | The Org Platform Enrich Pricing Log in Sign up GEn1E Lifesciences Teams Advisory Team Unverified Advisory Team 6 people · 0 jobs The Advisory Team at GEn1E Lifesciences provides strategic guidance and expert insights to drive the company's efforts in transforming promising research into groundbreaking therapies. Comprised of seasoned advisors, the team supports decision-making processes, helps navigate regulatory landscapes, and ensures alignment with industry best practices to address unmet medical needs. People ( 6 ) Alan J. Levy Advisor David Youn
About us | GEn1E Lifesciences Pipeline Phase 2 Study Differentiation AI Platform Partners About Media Contact Us Contact us About Our mission To accelerate novel therapies for patients with devastating diseases with no treatments. MEET our Team The Genies behind GEn1E Our team has strong domain expertise in developing novel, 1 st -in-class drugs as well as platforms Ritu Lal, PhD, MS CEO, Founder and Board Director Ritu has a track record of 3 FDA approvals in US and in Japan. Dr. Jeffrey Hasday Inventor of the p38 technology Prof. Paul Shapiro Inventor of the p38 technology Soujanya Bhumkar,